Open AccessLB100 ameliorates nonalcoholic fatty liver disease via the AMPK/Sirt1 pathway
Author(s) -
Xueyang Chen,
Changzhou Cai,
Mengli Yu,
Zemin Feng,
Yu-Wei Zhang,
Peihao Liu,
Hang Zeng,
Chaohui Yu
Publication year - 2019
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v25.i45.6607
Subject(s) - lipogenesis , endocrinology , nonalcoholic fatty liver disease , medicine , fatty acid synthase , beta oxidation , carnitine , fatty liver , ampk , peroxisome proliferator activated receptor , amp activated protein kinase , steatosis , biology , chemistry , protein kinase a , biochemistry , lipid metabolism , kinase , receptor , disease , metabolism
It is well known that nonalcoholic fatty liver disease (NAFLD) is associated with insulin resistance (IR). LB100, a serine/threonine protein phosphatase 2A (PP2A) inhibitor, is closely related to IR. However, there is little data regarding its direct influence on NAFLD.